Tardive Dyskinesia: Treatment with Aripiprazole

Na-Ri Kang, Moon-Doo Kim
Department of Psychiatry, Cheju National University Hospital, Jeju, Korea

Tardive dyskinesia is characterized by choreiform movements, or rhythmic abnormal involuntary movements of the face, mouth, tongue, trunk, and limbs. It is frequently associated with the use of neuroleptic medications. The choreiform movements are irreversible in some patients, even after the drug is withdrawn. Although no reliable treatment for tardive dyskinesia exists, atypical antipsychotics are associated with a significantly lower incidence of tardive dyskinesia than typical antipsychotics. Moreover, recent reports suggest that atypical antipsychotics may have a beneficial effect on tardive dyskinesia remission. Until recently, evidence for the effectiveness of aripiprazole on tardive dyskinesia has been mixed. Aripiprazole has a unique mechanism of action and has various effects in tardive dyskinesia. The drug acts as a partial D2 receptor agonist that can stabilize D2 up-regulation, and as a partial 5-HT1A receptor agonist and a 5-HT2A receptor antagonist, and can increase the release of dopamine in the striatum.

KEY WORDS: Aripiprazole; Tardive dyskinesia.

INTRODUCTION

Tardive dyskinesia (TD) is characterized by persistent slow writhing and sudden involuntary movements. The oral lingual region is the area most commonly involved, but the condition can affect nearly every muscle system, from the limbs to the respiratory muscles.1) The incidence of TD associated with atypical antipsychotics appears to be about one-fifth of that observed with first-generation “typical” antipsychotics.2-4) In a recent review of studies using comparable doses of antipsychotic drugs, the annualized incidence of TD was estimated to be 3.9% with atypical antipsychotics and 5.5% with conventional antipsychotics, showing an estimated 2- to 3-fold decline in the risk of TD with the administration of atypical antipsychotics.5)

TD is irreversible in some patients and persists even after medication is stopped;6,7) thus, it is important to prevent the development of TD.

The most important predictors of TD are older age, female gender, affective disorders, the presence of extrapyramidal side effects (EPS), diabetes mellitus, and certain parameters of neuroleptic exposure.8) Thus, it is critical that people who have these risk factors not be exposed to typical antipsychotics, which are associated with the development of TD symptoms.

Presently, no reliable, effective treatment is available for TD and the withdrawal of neuroleptics is often recommended.9) However, many patients cannot tolerate drug withdrawal and alternative atypical neuroleptics should be considered for this population.

Margolese et al.10) recommended the following treatment algorithm for cases that did not improve with conventional TD management: 1) discontinuation of anticholinergic therapy, 2) a switch to clozapine, 3) initiation of suppressive therapy using a conventional antipsychotic agent or tetrabenazine, and 4) addition of an experimental treatment, including donepezil, melatonin, branched-chain amino acids, vitamin E or vitamin B6, and drug reduction.

Thus, for patients who need antipsychotic medications, such as those with schizophrenia, bipolar illness, and many off-label conditions, atypical antipsychotic agents are the drugs of choice. Although atypical antipsychotics reduce the risk of extrapyramidal side effects and TD, they do not completely eliminate it, and the risk of developing TD remains a clinical concern.3)

Because atypical neuroleptics reduce the risk of TD, it may be reasonable to conclude that they are beneficial in...
Table 1. Cases of treatment of tardive dyskinesia with aripiprazole reported in the literature

| Author             | Year | Number of patients | Underlying disorder | Previous drug (dose, duration) | Type of dyskinesia | Dose/day (mg) | Treatment response                  |
|--------------------|------|--------------------|---------------------|--------------------------------|--------------------|--------------|------------------------------------|
| Duggal12)          | 2003 | 1 F                | 41                  | Haloperidol (not stated)       | Choreathetoid       | 30 mg/day    | Modest improvement                  |
| Grant e t al.13)   | 2005 | 1 F                | 54                  | Haloperidol (7.5 mg/day, 6 months) | Dykinetic oral      | 10 mg/day    | Disappeared and re-emerged only     |
| No auteurs listed.14) | 2008 | 1 M                | 65                  | Haloperidol (10 years), quetapine (400 mg/day, 3 years) | Blinking and a bucco-lingo-masticatory syndrome | 30 mg/day | Significant improvement              |
| Shan e t al.15)    | 2009 | 1 M                | 31                  | Risperidone (2 years), olanzapinie (not stated) | Oral-buccal-lingual dyskinesia | 30 mg/day | Disappeared                         |
| Osorio e t al.16)  | 2010 | 2 F, 1 M, 84, 85, 82| Agitation, mood swings, paranoid delusions (1), delusional disorder (1), bipolar disorder (1) | Haloperidol (2 mg, 10 years) (1), haloperidol (3 mg/day, 2 years) (1), haloperidol and thioridazine (30 years) (1) | Involuntary jaw movements (1), involuntary movements of mouth, face, trunk and limbs (1), orolingual dyskinetic movement (1) | 5 mg/day (1), 10 mg/day (2) | Gradually disappeared (1), Significant improvement (2) |
| Sharma et al.17)   | 2005 | 1 M                | 52                  | Ziprasidone (120 mg/day, 2 months) | Buccal-oral dyskinesia | 15 mg/day | Full remission                      |
| Witschy et al.18)  | 2005 | 45                 | Schizoaffective disorder, bipolar type | Haloperidol (for many years), risperidone (4 mg/day) | Not stated (AIMS 26) | 15 mg/day | Dramatically reduced                |
| Lykouras et al.19) | 2007 | 1 F                | 57                  | Quetapine (400 mg/day, 3 month), Ziprasidone (60 mg/day) | Abnormal movements of the jaw, lips, tongue, mouth, the upper extremities | 15 mg/day | Full remission                      |
| Caykoylu et al.20) | 2009 | 1 F                | 44                  | Risperidone (4 mg/day, 4 month) | Abnormal movements of the jaw, lips, mouth, tongue, low extremities | 15 mg/day | Full remission                      |

reversing the symptoms of the condition; however, their role in TD remission is unclear and controversial. Aripiprazole, an atypical antipsychotic, has a unique mechanism of action: it acts as a partial agonist at the D2 receptor and is a 5-HT2A receptor antagonist and a 5-HT1A receptor partial agonist.11) Several case studies have suggested that aripiprazole can improve TD caused by typical12-16) and atypical antipsychotics (Table 1).17-20)

Caykoylu et al.20) reported that a patient received risperidone at a dose of 4 mg and then, 4 months after the treatment dose was increased to 6 mg/day, abnormal movements of the jaw, lips, mouth, tongue, and lower extremities developed. The treatment regimen was changed from risperidone to aripiprazole. After 6 months of aripiprazole treatment (15 mg/day), the patient showed significant improvement in the severity of the TD. The authors suggested that the improvement was mediated by partial agonistic activity at the D2 receptors and proposed that aripiprazole be used to treat atypical antipsychotic-induced TD.

Another case study reported by Osorio et al.16) supported the role of aripiprazole as an effective treatment for TD. The patient was prescribed 5 mg/day aripiprazole and over the following month, the involuntary jaw movement
gradually disappeared. When the patient stopped treatment, TD symptoms re-emerged after 3 months, but disappeared once again when treatment was re-started. However, in these cases, it is difficult to determine whether the improvement was the result of the therapeutic action of aripiprazole or the effect of withdrawing a high-potency neuroleptic agent.

The prevalence of aripiprazole-associated TD has been reported to be between 0.2 and 3.4%.21,22) Cases of aripiprazole-induced TD have also been reported (Table 2),23-30) but these reports have some limitations, such as a small number of cases.

In summary, reports on the effectiveness of aripiprazole as a treatment for TD are mixed, and no systematic review of this topic has been reported. Thus, we reviewed the mechanism of action of aripiprazole according to the known pathophysiology of TD.

### METHODS

A search of MEDLINE from 2000 to 2010 was conducted using the terms “aripiprazole”, “tardive dyskinesia”, “pathophysiology”, and “treatment”. Twenty-nine articles were selected, and related articles were also reviewed for additional information. In total, 74 articles were selected.

### Tardive Dyskinesia Pathophysiology

The pathophysiology of TD is not fully understood and no single theory can account for all of the manifestations of the condition. The most widely accepted explanation is the dopamine receptor hypersensitivity hypothesis, which states that chronic neuroleptic treatment supersensitizes striatal dopamine receptors.31-33) However, several inconsistencies indicate that this hypothesis cannot fully explain the pathogenesis of TD. Nevertheless, D2 receptor hypersensitivity may be a necessary first step in the pathway that ultimately leads to the development of TD.33)
An earlier hypothesis suggested that TD resulted from neuroleptic-induced alterations in gamma-amino-butyric acid (GABA) transmission within the basal ganglia; it proposed that striatal GABA-containing neurons might be damaged. This explanation may be consistent with neuroleptic-induced degeneration of the striato-pallidal and/or striato-nigral GABAergic pathways.

McGeer EG and McGeer PL suggested that striatal excitotoxicity might play a role in the development of TD. Later studies showed that long-term treatment with neuroleptics increased striatal glutamate release and possible excitotoxicity, but the exact mechanisms underlying the excitotoxicity in chronic neurodegeneration and TD remain unclear.

Neurotransmitters in the serotonergic system may play a modulatory role in the pathogenesis of TD. The serotonin system interacts directly with dopaminergic neurons in the substantia nigra and ventral tegmental area. Serotonin (5-HT) modulates striatal dopamine release and can influence dyskinetic movements.

Spontaneous jaw movements in rats may be influenced by activation of the brain 5-HT system, particularly via 5-HT1A, 5-HT2C, and 5-HT3 receptors. Acute treatment with the 5-HT1A agonist, 8-OH-DPAT, reduced haloperidol-induced vacuous chewing movements in rats in a dose-dependent manner, indicating that the serotonergic system is involved in haloperidol-induced dyskinetic movements in the rat model.

**Putative Therapeutic Action of Aripiprazole in Tardive Dyskinesia**

**D2 Dopamine Receptor Partial Agonist Activity**

Chronic blockade of D2 dopamine receptors is associated with the development of TD in patients with chronic schizophrenia. This can be explained by the dopamine hypersensitivity hypothesis. As a dopamine D2 receptor partial agonist, aripiprazole can stabilize dopamine activity: it acts as a dopamine agonist in the hypodopaminergic state and as a dopamine antagonist in the hyperdopaminergic state. A dopamine D2 receptor partial agonist blocks the dopamine D2 receptor, but does not up-regulate it; thus, this property makes aripiprazole useful for patients who suffer from schizophrenia. Similarly, partial agonist activity at the D2 receptor does not up-regulate the D2 binding site or D2 mRNA. Thus, aripiprazole may prevent the development of TD and extrapyramidal side effects.

Because aripiprazole has been reported to normalize dopamine D2 up-regulation, the antipsychotic may improve the symptoms of TD induced by typical or atypical antipsychotics. In effective doses of 15-30 mg daily, aripiprazole occupies more than 80% of the striatal D2-like dopamine receptors; more than 90% occupancy at 30 mg daily has been reported in some cases. For most antipsychotics, high striatal D2 occupancy (>90%) is associated with the development of extrapyramidal side effects; however, aripiprazole does not increase the incidence of extrapyramidal side effects beyond that observed with placebo at this level of occupancy. This observation indicates that even at high striatal dopamine D2 receptor occupancy, aripiprazole blockade of D2 receptor-mediated neurotransmission is less than that of full antagonists because of its unique property as a partial dopamine agonist.

The rapid dissociation of aripiprazole could further explain this phenomenon. In contrast to typical antipsychotics, atypical antipsychotics dissociate rapidly from the D2 receptor. Rapid dissociation has been characterized as “hit-and-run” binding. The D2 receptor binding site of the atypical antipsychotics is smooth, and the drug fits loosely into the D2 receptor (the “hit”), so it slips off readily after binding only briefly and leaves (the “run”). This indicates that atypical antipsychotic drugs block D2 receptors only long enough to produce an antipsychotic effect, then dissociate before extrapyramidal side effects develop. It has been suggested that before the next pulse of the drug, endogenous dopamine in the nigrostriatal dopamine system may bind the receptor and prevent motor side effects. Thus, although aripiprazole has a high D2 receptor occupancy, rapid dissociation means that the antipsychotic binds to the D2 receptor for a short period of time. Rapid dissociation can explain the lower incidence of tardive dyskinesia, but it does not explain the therapeutic effect of aripiprazole on tardive dyskinesia.

**5-HT1A Receptor Partial Agonist Activity**

The 5-HT1A and 5-HT2A receptors have different effects on dopamine and glutamate release. Activation of the 5-HT1A autoreceptors disinhibits the dopamine neuron, thereby increasing dopamine release. The partial agonist action of aripiprazole stimulates 5-HT1A receptor-mediated release of dopamine in the striatum and alleviates extrapyramidal side effects.

Aripiprazole’s low level of catalepsy is partially reversed by 5-HT1A antagonists, indicating that the partial agonist activity of aripiprazole at the 5-HT1A receptor plays an important role in the low incidence of ex-
trapyramidal symptoms.\textsuperscript{56-59} Eskow \textit{et al.}\textsuperscript{60} reported in a preclinical study that buspirone, a partial 5-HT\textsubscript{1A} agonist, improved 1-3,4-dihydroxyphenylalanine (1-DOPA)-induced dyskinesia and motor fluctuations, indicating that a partial 5-HT\textsubscript{1A} agonist may be beneficial in the treatment of tardive dyskinesia. The authors suggested two possible explanations for their results: stimulation of postsynaptic 5-HT\textsubscript{1A} receptors in the corticostriatal glutamatergic pathway reduced excessive glutamate release in the striatum, or presynaptic 5-HT\textsubscript{1A} receptors within the striatal thronomes inhibited glutamate release into the striatum and decreased the pathological striatal output responsible for dyskinetic movement.

These findings indicate that the 5-HT\textsubscript{1A} partial agonist property of aripiprazole may mediate the drug’s beneficial effect on dyskinetic movements\textsuperscript{61} and suggest that drugs targeting 5-HT\textsubscript{1A} receptors provide a promising non-dopaminergic therapy for dyskinetic movement.\textsuperscript{60} Although several studies indicate that 5-HT\textsubscript{1A} partial agonists decrease the incidence of extrapyramidal side effects, including tardive dyskinesia, evidence that they play a role in the remission of tardive dyskinesia is not convincing.

5–HT\textsubscript{2A} Receptor Antagonist Activity

Aripiprazole acts as an antagonist at the 5-HT\textsubscript{2A} receptor and releases dopamine by disinhibiting dopaminergic neurons.\textsuperscript{55} Atypical antipsychotic drugs cause fewer extrapyramidal side effects, including TD, than do typical antipsychotics; however, drugs with low anti-dopaminergic (D\textsubscript{2}) affinity and high anti-serotonergic (5-HT\textsubscript{2A}) affinity are associated with the lowest extrapyramidal symptoms, particularly tardive dyskinesia. Tarsy \textit{et al.}\textsuperscript{62} ranked antipsychotic drugs according to the risk of extrapyramidal symptoms in the following order: clozapine <quetiapine <olanzapine=ziprasidone <risperidone. However, aripiprazole had not yet been approved for clinical practice when that review was published.

Second-generation atypical antipsychotics differ from typical antipsychotics in that they have a high 5-HT\textsubscript{2A} : D\textsubscript{2} affinity ratio and a low affinity for the dopamine D\textsubscript{2} receptor.\textsuperscript{54} In contrast, aripiprazole has a low 5-HT\textsubscript{2A} : D\textsubscript{2} affinity ratio and a high affinity for the dopamine D\textsubscript{2} receptor. Because aripiprazole is a partial dopamine agonist, it seems unlikely that the drug’s high D\textsubscript{2} receptor affinity is the result of higher dopamine receptor antagonist activity than other atypical antipsychotics.\textsuperscript{63} Previous research suggests that aripiprazole-induced moderate 5\textsubscript{2A} receptor blockade accounts for the drug’s low incidence of extrapyramidal symptoms, including tardive dyskinesia, and its beneficial therapeutic effect, but this association remains unproven.

Putative Mechanisms Underlying Aripiprazole–induced TD

Recently, Peña \textit{et al.}\textsuperscript{22} reported that eight of the 236 patients had aripiprazole-associated TD. Of these, five patients were classified as having definite aripiprazole-associated TD because their movement disorder occurred after exclusive exposure to aripiprazole, and three patients were classified as probable. However, most previous case reports of TD associated with aripiprazole either failed to show a convincing temporal correlation of symptom onset with administration of the drug or concerned patients who had been previously exposed to conventional antipsychotics.\textsuperscript{25}

The finding that the incidence of aripiprazole-induced TD is similar to that of a placebo led us to examine non-drug related risk factors for tardive dyskinesia. Risk factors for tardive dyskinesia include older age, preexisting movement or neurodegenerative disorders, female gender, the presence of affective illness, and exposure to neuroleptic drugs for more than 6 months.\textsuperscript{4,64} Several case reports of aripiprazole-induced tardive dyskinesia indicated that the patients had at least one of these risk factors.\textsuperscript{26,29}

Furthermore, an association has been reported between a specific D\textsubscript{3} receptor polymorphism and the risk of TD. Ser9Gly homozygosity or heterozygosity for the DRD3-gly allele of the D\textsubscript{3} genetic locus has been reported with antipsychotic medications.\textsuperscript{65} This suggests that the development of TD may be the result of vulnerability due to this polymorphism, rather than the action of aripiprazole itself. Alternatively, aripiprazole-induced TD may be explained by the drug’s mechanisms of action.

High Dopamine Receptor Occupancy and Partial Agonist Effect on Dopamine Hypersensitivity

Kapur \textit{et al.}\textsuperscript{66} reported that extrapyramidal side effects increase significantly when D\textsubscript{2} occupancy exceeds 78%. Mamo \textit{et al.}\textsuperscript{64} recently reported that the striatal D\textsubscript{2} receptor occupancy of aripiprazole was high in the putamen, 87%; caudate, 93%; and ventral striatum, 91%.

Partial agonists have the intrinsic ability to act as both agonists and antagonists, depending on neurotransmitter levels. Thus, it is possible that the partial dopamine receptor agonist action of aripiprazole might induce mild extrapyramidal symptoms in patients who had no prior exposure to D\textsubscript{2} antagonists or were on an initiation dose.\textsuperscript{55}
In cases where the dopamine receptor is up-regulated or hypersensitive following chronic antipsychotic treatment, the high dopamine receptor occupancy and partial agonist action of aripiprazole might enhance hypersensitivity in the nigrostriatal dopaminergic system, leading to TD.67)

Balance between Dopamine D₁ and D₂ Receptors

Studies of the basal ganglia and movement disorders suggest that the final common pathway for dyskinesia is increased activation of the D₁-mediated striatonigral (or “direct”) pathway and blockade of the inhibitory D₂-mediated striatopallidal (or “indirect”) loop. Stimulation of these pathways may cause D₁ receptor overactivation.

In the presence of D₂ receptor blockade, repetitive stimulation of the D₁ receptor sensitizes D₁-mediated striatal output. The kindling model suggests that this mechanism may cause the development of tardive dyskinesia (including tardive dystonia).71)

While D₂ receptors are occupied by chronic antipsychotic medication, endogenous dopamine may stimulate D₁ receptors. Thus, despite aripiprazole’s D₂ partial agonist activity, chronic treatment with the drug may disrupt the balance of D₁- and D₂-mediated striatal outputs by selectively blocking D₂ receptors.72)

Lack of Anticholinergic Activity

Muscarinic receptor blockade may protect against the extrapyramidal side-effects associated with antipsychotic drug use.73) Aripiprazole has not been found to have anticholinergic activity at clinically effective doses, and this may play a role in aripiprazole-induced TD.74)

Limitations of the Present Review

The pathophysiology of tardive dyskinesia is not well understood and no randomized, placebo-controlled, double-blind study has been reported examining the therapeutic efficacy of aripiprazole for the treatment of tardive dyskinesia. Thus, this review is based primarily on case reports of tardive dyskinesia treated with aripiprazole. The limited information available did not allow us to determine whether any improvement was the result of the therapeutic action of aripiprazole or an effect of withdrawing a high-potency neuroleptic agent.

CONCLUSION

Aripiprazole has a unique mechanism of action as a partial agonist at the D₂ receptor, a 5-HT₁A receptor antago-
Tardive Dyskinesia: Treatment with Aripiprazole

2005;7:36.

18. Witschy JK, Winter AS. Improvement in tardive dyskinesia with aripiprazole use. Can J Psychiatry 2005;50:188.

19. Lykouras L, Rizos E, Gournellis R. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1535-1536.

20. Caykoylu A, Ekinci O, Yilmaz E. Resolution of risperidone-induced tardive dyskinesia with a switch to aripiprazole monotherapy. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:571-572.

21. Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs 2004;64:1715-1736.

22. Peña MS, Yalto TC, Jankovic J. Tardive dyskinesia and other movement disorders associated to aripiprazole. Mov Disord 2011;26:147-152.

23. Maytal G, Ostacher M, Stern TA. Aripiprazole-related tardive dyskinesia. CNS Spectr 2006;11:435-439.

24. Abbassian C, Power P. A case of aripiprazole and tardive dyskinesia. J Psychopharmacol 2009;23:214-215.

25. Evcimen YA, Evcimen H, Holland J. Aripiprazole-induced tardive dyskinesia: the role of tamoxifen. Am J Psychiatry 2007;164:1436-1437.

26. Zaidi SH, Faruqui RA. Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis. Brain Inj 2008;22:99-102.

27. Lungu C, Aia PG, Shih LC, Esper CD, Factor SA, Tarsy D. Tardive dyskinesia due to aripiprazole: report of 2 cases. J Clin Psychopharmacol 2009;29:185-186.

28. Wang LJ, Ree SC, Chen CK. Courses of aripiprazole-associated tardive dyskinesia: report of two cases. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:743-744.

29. Schwartz T, Raza S. Aripiprazole (abilify) and tardive dyskinesia. P T 2008;33:32-34.

30. Sajbel TA, Cheney EM, DeQuardo JR. Aripiprazole-related tardive dyskinesia. Ann Pharmacother 2005;39:200-201.

31. Klawans HL Jr, Rubovits R. An experimental model of tardive dyskinesia. J Neuro Transm 1972;33:235-246.

32. Tarsy D, Baldessarini RJ. Pharmacologically induced behavioural supersensitivity to apomorphine. Nat New Biol 1973;245:262-263.

33. Schatzberg AF, Nemeroff CB. American Psychiatric Press. The American psychiatric press textbook of psychopharmacology. Washington, DC: American Psychiatric Press; 1995.

34. Fibiger HC, Lloyd KG. Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci 1984;7:462-464.

35. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington’s chorea by intrastratial injections of glutamic and kainic acids. Nature 1976;263:517-519.

36. Moghaddam B, Bunney BS. Depolarization inactivation of dopamine neurons: terminal release characteristics. Synapse 1993;14:195-200.

37. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994;14:4159-4166.

38. See RE, Chapman MA. Chronic haloperidol, but not clozapine, produces altered oral movements and increased extracellular glutamate in rats. Eur J Pharmacol 1994;263:269-276.

39. See RE, Lynch AM. Chronic haloperidol potentiates stimulated glutamate release in caudate putamen, but not prefrontal cortex. Neuropsychopharmacology 1995;6:1793-1798.

40. Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog Neurobiol 2000;61:525-541.

41. Barnes JM, Barnes NM, Cooper SJ. Behavioural pharmacology of 5-HT3 receptor ligands. Neurosci Biobehav Rev 1992;16:107-113.

42. Egan MF, Apud J, Wyatt RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583-609.

43. Selbyl JG, Glazer WM, Innis RB. Serotonin function in tardive dyskinesia. Psychiatr Annals 1989;19:310-314.

44. Gong L, Kostrzewa RM, Fuller RW, Perry KW. Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J Pharmacol Exp Ther 1992;261:1000-1007.

45. Eberle-Wang K, Lucki I, Chesselet MF. A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia. Neuroscience 1996;72:117-128.

46. Naidu PS, Kulkarni SK. Reversal of neuroleptic-induced orofacial dyskinesia by 5-HT3 receptor antagonists. Eur J Pharmacol 2001;420:113-117.

47. Soares-Weiser K, Fernandez HH. Tardive dyskinesia. Semin Neurol 2007;27:159-169.

48. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411.

49. Tamminga CA, Carlsson A. Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 2002;1:141-147.

50. Inoue A, Miki S, Seto M, Kikuchi T, Morita S, Ueda H, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105-111.

51. Sharma V. Treatment-emergent tardive dyskinesia withquetiapine in mood disorders. J Clin Psychopharmacol 2003;23:415-417.

52. Yokoi F, Grindeur G, Bzieker K, Stephane M, Dogan AS, Dannals RF, et al. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology 2002;27:248-259.

53. Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Eur Neuropsychopharmacol 2000;10(Suppl 3):S309-S310.

54. Petrie JL, Saha AR, McEvoy JP. Aripiprazole, a new atypical antipsychotic: phase 2 clinical trial results. Eur Neuropsychopharmacol 1997;7(Suppl 2):S227.

55. Stahl SM. Stahl’s Essential Psychopharmacology, 3/E: Neuroscientific Basis and Practical Applications. Cambridge University Press; 2008. p.345-382.

56. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004;10:317-336.

57. Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, Ander G, Mertens J, et al. Aripiprazole, a new atypical antipsychotic, reduces levodopa-induced dyskinesia in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189:259-266.

58. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:1159-1172.
59. Bardin L, Kleven MS, Barret-Grévoz C, Depoortère R, Newman-Tancredi A. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology 2006;31:1869-1879.

60. Eskow KL, Gupta V, Alam S, Park JY, Bishop C. The partial 5-HT1A agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 2007;87:306-314.

61. Rajarethinam R, Dziuba J, Manji S, Pizzuti A, Lachover L, Keshavan M. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. World J Biol Psychiatry 2009;10:416-419

62. Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 2002;16:23-45.

63. Dolder CR, Jeste DV. Incidence of tardive dyskinesia with typical versus atypical antipsychotics in very high risk patients. Biol Psychiatry 2003;53:1142-1145.

64. Mamo D, Graff A, Mizrahi R, Shammi CM, Romeyer F, Kapur S. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry 2007;164:1411-1417.

65. Lerer B, Segman RH, Fangerau H, Daly AK, Basile VS, Cavallaro R, et al. Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105-119.

66. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520.

67. Wang L, Ree SC, Chen CK. Courses of aripiprazole-associated tardive dyskinesia: report of two cases. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:743-744.

68. Albin RL, Young AB, PenneyJB. The functional neuroanatomy of the basal ganglia disorders. Trends Neurosci 1989;12:366-375.

69. Crossman AR. A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson’s disease: implications for future strategies in treatment. Mov Disord 1990;5:100-108.

70. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.

71. Egan MF, Hyde TM, Albers GW, Elkashef A, Alexander RC, Reeve A, et al. Treatment of tardive dyskinesia with vitamin E. Am J Psychiatry 1992;149:773-777.

72. Trugman JM, Leadbetter R, Zalis ME, Burgdorf RO, Wooten GF. Treatment of severe axial tardive dystonia with clozapine: case report and hypothesis. Mov Disord 1994;9:441-446.

73. Lim HK, Pae CU, Lee C, Lee CU. Tardive dystonic symptoms associated with aripiprazole treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:589-590.

74. Chew ML, Mulsant BH, Pollock BG, Lehman ME, Green- span A, Kirshner MA, et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr Res 2006;88:63-72.